CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Incyte Corporation
Dren Bio
AVM Biotechnology Inc
Lyell Immunopharma, Inc.
Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc.
Merck Sharp & Dohme LLC
Genmab
Arovella Therapeutics Ltd
Bristol-Myers Squibb
SecuraBio
Artiva Biotherapeutics, Inc.
AstraZeneca
Hoffmann-La Roche
Hoffmann-La Roche
AvenCell Therapeutics, Inc.
Acerta Pharma BV
Vironexis Biotherapeutics Inc.
Pfizer
VIVUS LLC
Treeline Biosciences, Inc.
ADC Therapeutics S.A.
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Taiho Oncology, Inc.
Nurix Therapeutics, Inc.
Fate Therapeutics
Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc.